BP-002
Respiratory Syncytial Virus (RSV)
Phase 1Active
Key Facts
About BioNet Asia
A private biotech delivering recombinant and mRNA vaccines for respiratory diseases, with an EU‑approved pertussis product.
View full company profileTherapeutic Areas
Other Respiratory Syncytial Virus (RSV) Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical Program | Biotron | Preclinical |
| IN-002 | Inhalon Biopharma | Pre-IND |
| BLB201 | CyanVac | Phase 1/2 |
| AI Programme - RSV | Poolbeg Pharma | Discovery |
| Oral RSV Vaccine | Vaxart | Preclinical/Phase 1 |